サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1792801

非嚢胞性線維症気管支拡張症の世界市場

Non-Cystic Fibrosis Bronchiectasis

出版日
ページ情報
英文 396 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.34円
非嚢胞性線維症気管支拡張症の世界市場
出版日: 2025年08月18日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 396 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

非嚢胞性線維症気管支拡張症の世界市場は2030年までに45億米ドルに達する見込み

2024年に36億米ドルと推定される非嚢胞性線維症気管支拡張症の世界市場は、2024年から2030年にかけてCAGR 3.8％で成長し、2030年には45億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである外科治療は、CAGR 5.2%を記録し、分析期間終了時には13億米ドルに達すると予測されます。理学療法治療分野の成長率は、分析期間中CAGR 2.3％と推定されます。

米国市場は9億7,970万米ドルと推定、中国はCAGR 7.3%で成長予測

米国の非嚢胞性線維症気管支拡張症市場は、2024年に9億7,970万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9億2,090万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5％と3.0％と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界の非嚢胞性線維症気管支拡張症市場- 主要動向と促進要因のまとめ

疾患認知は臨床認知をどのように促進するか？

非嚢胞性線維症気管支拡張症は、不可逆的な気道拡張、頻繁な感染症、持続的な喀痰分泌を特徴とする慢性呼吸器疾患です。COPD、喘息、再発性呼吸器感染症などと症状が重複するため、診断されないことが多いです。最近の画像診断、特に高分解能CTスキャンの進歩により、気管支拡張症は別個の疾患として認識されるようになりました。肺専門医や一般開業医の間で認知度が高まるにつれて、より多くの症例が同定され、正確に管理されるようになってきています。

継続的な医学教育と更新された臨床ガイドラインは、認知度の向上に極めて重要な役割を果たしています。現在、医師は呼吸器症状を繰り返す患者に対して気管支拡張症を考慮する傾向が強くなっています。また、患者教育キャンペーンや呼吸器学会は、慢性の咳や痰がある人に評価を受けるよう促しており、病気の早期発見をさらに後押ししています。

疾患管理においてどのような治療革新が生まれているか？

非嚢胞性線維症気管支拡張症の治療は従来、気道確保技術、抗生物質、増悪の管理が中心でした。しかし、いくつかの新しい治療アプローチが発展しつつあります。吸入マクロライドや長時間作用型抗生物質は、気道マイクロバイオーム管理を改善しつつ、全身曝露を最小限にするよう改良されつつあります。さらに、粘液活性剤や高浸透圧生理食塩水製剤は、より効果的な粘液クリアランスのために調整されつつあります。

好中球経路を調節するように設計された標的抗炎症療法や生物学的製剤の研究も進行中です。これらの治療は、宿主防御を損なうことなく慢性炎症を軽減することを目的としています。さらに、新しい非侵襲的な人工呼吸器や気道確保装置が登場し、個人に合わせた呼吸サポートを提供し、患者のQOLを向上させています。増悪頻度を減らし、肺機能を促進するために、監視下での運動や肺リハビリテーションなどの支援プログラムが治療レジメンに組み込まれつつあります。

なぜ患者中心の集学的ケアモデルが台頭しているのか？

非嚢胞性線維症気管支拡張症の効果的な管理には、包括的で患者中心のアプローチが必要です。呼吸器科医、理学療法士、感染症専門医、栄養士などの集学的チームが呼吸器クリニックやケアセンターの標準となりつつあります。これらのチームは、気道確保計画、抗生物質レジメン、栄養カウンセリング、合併症管理などを調整し、転帰を最適化します。

デジタルケアツールも患者サポートを強化しています。モバイルアプリは症状、服薬アドヒアランス、理学療法ルーチンの追跡に役立ちます。遠隔医療相談や遠隔モニタリングは、増悪時にタイムリーな介入を可能にし、病院の再入院を減らします。患者支援コミュニティと疾患登録は、治療の継続性と実世界でのデータ収集努力をさらに強化しています。

非嚢胞性線維症気管支拡張症市場の成長は、いくつかの要因によってもたらされます。

臨床意識の高まりと画像診断の改善により、発見率が拡大し、患者層が拡大しています。標的を絞った吸入抗生物質、抗炎症剤、粘液除去療法の開発が治療の選択肢を増やしています。集学的ケアモデルとデジタルヘルスプラットフォームの統合により、管理効果と患者エンゲージメントが向上しています。さらに、新規の生物学的製剤や気道補助デバイスを評価する臨床試験がパイプラインの活性化に拍車をかけています。公衆衛生システムによる慢性呼吸器疾患管理の重視は、気管支拡張症治療のインフラと治療への投資を引き続き支えています。

セグメント

治療（手術治療、理学療法治療、ワクチン治療、気道薬物療法治療、抗生物質治療、その他の治療）;診断（CTスキャン診断、気管支鏡診断、胸部X線診断、肺機能診断、喀痰培養検査診断、血液検査診断、その他の診断タイプ）;エンドユーザー（病院・診療所エンドユーザー、外来手術センターエンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • Armata Pharmaceuticals
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • CSL Behring
  • GlaxoSmithKline plc
  • Haisco Pharmaceutical Group
  • Infex Therapeutics
  • Insmed Incorporated
  • NovaBiotics
  • Novartis AG
  • Parion Sciences Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Renovion Inc.
  • Sanofi S.A.
  • SolAeroMed Inc.
  • Teva Pharmaceutical Industries
  • Verona Pharma plc
  • Zambon S.p.A.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37503

Global Non-Cystic Fibrosis Bronchiectasis Market to Reach US$4.5 Billion by 2030

The global market for Non-Cystic Fibrosis Bronchiectasis estimated at US$3.6 Billion in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Physiotherapy Treatment segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$979.7 Million While China is Forecast to Grow at 7.3% CAGR

The Non-Cystic Fibrosis Bronchiectasis market in the U.S. is estimated at US$979.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$920.9 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Non Cystic Fibrosis Bronchiectasis Market - Key Trends & Drivers Summarized

How Is Disease Awareness Driving Clinical Recognition?

Non cystic fibrosis bronchiectasis is a chronic respiratory condition marked by irreversible airway dilation, frequent infections, and persistent sputum production. It often goes undiagnosed due to overlapping symptoms with COPD, asthma, or recurrent respiratory infections. Recent improvements in diagnostic imaging, particularly high-resolution CT scans, have led to better recognition of bronchiectasis as a distinct condition. As awareness grows among pulmonologists and general practitioners, more cases are being identified and accurately managed.

Continuing medical education and updated clinical guidelines have played a pivotal role in raising awareness. Physicians are now more likely to consider bronchiectasis in patients with recurrent respiratory symptoms. Patient education campaigns and respiratory societies are also encouraging individuals with chronic cough and sputum to seek evaluation, further supporting earlier detection of the disease.

What Treatment Innovations Are Emerging in Disease Management?

Treatment for non cystic fibrosis bronchiectasis traditionally focuses on airway clearance techniques, antibiotics, and managing exacerbations. However, several novel therapeutic approaches are evolving. Inhaled macrolides and long acting antibiotics are being refined to minimize systemic exposure while improving airway microbiome management. Additionally, mucoactive agents and hyperosmolar saline formulations are being tailored for more effective mucus clearance.

Research into targeted anti inflammatory therapies and biologics designed to modulate neutrophil pathways is also underway. These treatments aim to reduce chronic inflammation without compromising host defense. Furthermore, new non invasive ventilation and airway clearance devices are emerging, providing personalized respiratory support and improving patient quality of life. Supportive programs, such as supervised exercise and pulmonary rehabilitation, are being integrated into treatment regimens to reduce exacerbation frequency and promote lung function.

Why Are Patient-Centric and Multidisciplinary Care Models on the Rise?

Effective management of non cystic fibrosis bronchiectasis requires a comprehensive, patient centric approach. Multidisciplinary teams - including pulmonologists, physiotherapists, infectious disease specialists, and nutritionists - are becoming standard in respiratory clinics and care centers. These teams coordinate airway clearance plans, antibiotic regimens, nutritional counseling, and comorbidity management to optimize outcomes.

Digital care tools have also enhanced patient support. Mobile apps help track symptoms, medication adherence, and physiotherapy routines. Telehealth consultations and remote monitoring enable timely intervention during exacerbations, reducing hospital readmissions. Patient support communities and disease registries are further strengthening treatment continuity and real world data collection efforts.

Growth in the non cystic fibrosis bronchiectasis market is driven by several factors.

Rising clinical awareness and improved diagnostic imaging are expanding detection rates and broadening patient pools. Development of targeted inhaled antibiotics, anti inflammatory agents, and mucus clearing therapies is enhancing treatment options. Integration of multidisciplinary care models and digital health platforms is improving management effectiveness and patient engagement. Additionally, clinical trials evaluating novel biologics and airway support devices are fueling pipeline activity. Greater emphasis on chronic respiratory disease management by public health systems continues to support investment in bronchiectasis care infrastructure and therapies.

SCOPE OF STUDY:

The report analyzes the Non-Cystic Fibrosis Bronchiectasis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment, Other Treatments); Diagnosis (CT Scan Diagnosis, Bronchoscopy Diagnosis, Chest X-Ray Diagnosis, Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Armata Pharmaceuticals
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • CSL Behring
  • GlaxoSmithKline plc
  • Haisco Pharmaceutical Group
  • Infex Therapeutics
  • Insmed Incorporated
  • NovaBiotics
  • Novartis AG
  • Parion Sciences Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Renovion Inc.
  • Sanofi S.A.
  • SolAeroMed Inc.
  • Teva Pharmaceutical Industries
  • Verona Pharma plc
  • Zambon S.p.A.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Non-Cystic Fibrosis Bronchiectasis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates of Chronic Respiratory Conditions Drive Attention Toward Non-Cystic Fibrosis Bronchiectasis
    • Increased Use of High-Resolution CT Scans Enhances Detection and Differentiation of Non-CF Bronchiectasis
    • Growing Geriatric Population and Associated Lung Disorders Spur Market Demand for Long-Term Respiratory Care
    • Rising Incidence of Recurrent Respiratory Infections Throws the Spotlight on Early-Stage Identification and Treatment
    • Expansion of Multidisciplinary Care Models Supports Comprehensive Management of Non-CF Bronchiectasis Patients
    • Adoption of Inhaled Antibiotic Therapies Strengthens Targeted Treatment Strategies for Infection Control
    • Ongoing Clinical Trials Exploring Anti-Inflammatory Agents Stimulate Pipeline Innovation
    • Increased Use of Airway Clearance Devices and Nebulizer Systems Enhances Symptom Management
    • Focus on Reducing Hospital Readmission Rates Drives Use of Maintenance Therapies and Prophylactic Treatments
    • Growing Research into Non-Tuberculous Mycobacterial (NTM) Infections Linked to Bronchiectasis Expands Therapeutic Approaches
    • Integration of Personalized Care Protocols Supports Better Outcomes and Patient Adherence
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-Cystic Fibrosis Bronchiectasis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Physiotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Physiotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Physiotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vaccination Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Airway Pharmacotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Airway Pharmacotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Airway Pharmacotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Antibiotics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Lung Function Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Lung Function Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Lung Function Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Sputum Culture Test Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Sputum Culture Test Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Sputum Culture Test Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Blood Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Blood Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Blood Tests Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Diagnosis Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for CT Scan Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for CT Scan Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for CT Scan Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Bronchoscopy Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Bronchoscopy Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Bronchoscopy Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Chest X-Ray Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Chest X-Ray Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Chest X-Ray Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 101: France Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: France 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: France 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: France 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Germany 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Italy 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Italy 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 128: UK Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: UK 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 131: UK Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: UK 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: UK 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Spain 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Spain 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Spain 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Russia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Russia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Russia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Australia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Australia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Australia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 185: India Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: India 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 188: India Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: India 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: India 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: South Korea 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: South Korea 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: South Korea 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Argentina 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Argentina 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Argentina 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Brazil 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Brazil 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Brazil 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Mexico 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Mexico 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Mexico 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Iran 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Iran 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Iran 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Israel 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Israel 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Israel 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: UAE 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: UAE 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: UAE 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Non-Cystic Fibrosis Bronchiectasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Non-Cystic Fibrosis Bronchiectasis by Treatment - Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Africa 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Physiotherapy Treatment, Vaccination Treatment, Airway Pharmacotherapy Treatment, Antibiotics Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Africa 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by Diagnosis - Percentage Breakdown of Value Sales for Lung Function Diagnosis, Sputum Culture Test Diagnosis, Blood Tests Diagnosis, Other Diagnosis Types, CT Scan Diagnosis, Bronchoscopy Diagnosis and Chest X-Ray Diagnosis for the Years 2014, 2025 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Non-Cystic Fibrosis Bronchiectasis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Africa 16-Year Perspective for Non-Cystic Fibrosis Bronchiectasis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION